Thiamine-responsive megaloblastic anemia syndrome

MONDO:0009575

Thiamine-responsive megaloblastic anemia (TRMA) is characterized by a triad of megaloblastic anemia, non-type I diabetes mellitus, and sensorineural deafness.

Also known as: Rogers syndrome, THMD1, TRMA, thiamine metabolism dysfunction syndrome 1, thiamine-responsive anemia syndrome, thiamine-responsive megaloblastic anemia syndrome, thiamine-responsive megaloblastic anemia with diabetes mellitus and sensorineural deafness, thiamine-responsive myelodysplasia

69 clinical trials for this condition and its sub-types.

Follow this condition — get notified about new trials

Broader categories

Disease (618) Metabolic disease (215) Anemia (203) Hereditary disease (172) Hematologic disorder (160) Inborn errors of metabolism (42) Human disease (14) Autosomal recessive disease (4) Deficiency anemia (2) Disease of genetic or genomic mechanism (2)

Trials to join now! 34 Not yet recruiting 5 Not yet finished but already full! 8 Completed 21 Terminated 1

Can extra care after transplant help older patients live better?

Disease control Terminated

This study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…

Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC

Thiamine-responsive megaloblastic anemia syndrome

Broader categories

Can extra care after transplant help older patients live better?